氢化可的松联合乌司他丁治疗脓毒性休克的效果

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (711 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore clinical efficacy of Hydrocortisone combined with Ulinastatin in treatment of septic shock. Methods From September 2015 to September 2018, 80 cases with septic shock admitted to Guangxi Zhuang Autonomous Region Liuzhou People′s Hospital were selected. According to the random number table method, they were divided into the control group (40 cases) and the observasion group (40 cases). Both groups were given conventional treatment, the control group was given Hydrocortisone on the basis of conventional treatment, and the observasion group was treated with Hydrocortisone combined with Ulinastatin. The two groups were continuously treated for 2 weeks. Clinical efficacy was evaluated after treatment. The mechanical ventilation time, hospitalization time were compared between the two groups. The acute physiology and chronic health evaluation Ⅱ (APACHEⅡ) score, systolic blood pressure (SBP), white blood cell count (WBC), levels of serum C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and procalcitonin (PCT) of the two groups before and after treatment were compared. The occurrence of adverse reactions and 28-day mortality during the treatment of the two groups was recorded. Results The total clinical effective rate of the observasion group was significantly higher than that of the control group, the difference was statistically significant (P < 0.05). The mechanical ventilation time and hospitalization time of the observasion group were significantly shorter than those of the control group, the differences were statistically significant (all P < 0.05). The APACHEⅡ score, WBC of the observasion group were significantly shorter than those of the control group, SBP of the observasion group was significantly higher than that of the control group, the differences were statistically significant (all P < 0.05). The level of serum CRP, TNF-α and PCT of the observasion group were significantly lower than those of the control group, the differences were statistically significant (all P < 0.05). The 28-day mortality of the observasion group was lower than that of the control group, the difference was statistically significant (P < 0.05). There was no obvious adverse reactions in the course of treatment in both groups. Conclusion Hydrocortisone combined with Ulinastatin is significantly effective in treatment of septic shock, which can significantly alleviate the illness, improve the body′s level of inflammation and reduce mortality.

Key words： Sepsis Shock Hydrocortisone Ulinastatin Efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XIONG Minjun LYU Guangyu WANG Xiaoyuan WEI Yin WEI Shujing

Cite this article:

XIONG Minjun LYU Guangyu WANG Xiaoyuan WEI Yin WEI Shujing. Effect of Hydrocortisone combined with Ulinastatin in treatment of septic shock[J]. 中国医药导报, 2019, 16(32): 111-114.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I32/111

[1] 马黎霞，邓烈华.脓毒血症液体管理现状与研究进展[J].中华实用诊断与治疗杂志，2016，30（3）：222-224.
[2] 王喜梅，明志浩，尹辉明，等.脓毒血症的流行病学与临床治疗进展[J].中华医院感染学杂志，2017，27（15）：3597-3600.
[3] 黄盛.小剂量糖皮质激素在脓毒血症患者治疗中的临床分析[J].中外医疗，2017，36（35）：153-154，158.
[4] 罗秀贞.连续性血液净化在治疗重症脓毒血症中的应用[J].基层医学论坛，2018，22（4）：572-573.
[5] 毛刚，吴清安，刘磊.乌司他丁的药理作用机制及临床应用进展[J].山东医药，2015，55（30）：94-96.
[6] 中华医学会重症医学分会.中国严重脓毒症/脓毒性休克治疗指南（2014）[J].中华危重病急救医学，2015，27（6）：401-426.
[7] 孙传兴.临床疾病诊断依据治愈好转标准[M].北京：人民军医出版社，2006：339.
[8] 李丽，朱勇，鲁晓擘，等.CRRT联合乌司他丁对严重脓毒血症患者APACHEⅡ、SOFA和Marshall评分及炎性因子的影响[J].疑难病杂志，2018，17（11）：1242-1246.
[9] 杨兴才，楼丹飞，韦红，等.抗炎合剂对脓毒症患者血管内皮细胞功能的影响[J].国际中医中药杂志，2018，40（7）：587-591.
[10] 张晓宁，孟祥忠，高胜庭，等.血小板相关参数在脓毒症与脓毒性休克患者间变化差异及其与预后的相关性分析[J].临床和实验医学杂志，2017，16（16）：1638-1641.
[11] 付跃峰，孔令博，郭楠，等.老年脓毒症休克的中西医结合救治体会[J].中国医药导报，2019，16（9）：127-130.
[12] 姜相明，田惠玉，赵红敏，等.脓毒症休克患者早期小剂量糖皮质激素治疗价值的研究[J].河北医药，2018，40（15）：2279-2283.
[13] 姜相明，游道峰，赵红敏，等.早期小剂量糖皮质激素对脓毒症休克患者血流动力学及预后的影响[J].重庆医学，2017，46（7）：901-904.
[14] 李亚映奇，刘宏宇.感染性休克的常规治疗及臭氧在治疗中的应用进展[J].医学综述，2018，24（18）：3669-3672.
[15] 王秋义，王庆树.氢化可的松琥珀酸钠给药方式差异对重症脓毒血症继发休克患者生命体征、动态血糖指标及死亡率的影响[J].中国现代医学杂志，2017，27（13）：82-85.
[16] 陶广华，张随随，朱玲钰，等.乌司他丁的药理作用机制及临床应用进展[J].中国药房，2017，28（35）：5020-5023.
[17] 陈维生，钟耀区，曾景，等.血必净注射液联合乌司他丁注射液治疗脓毒血症的临床可行性研究[J].中国现代药物应用，2018，12（20）：76-77.
[18] 伍增龙，黄永鹏，马俊，等.乌司他丁联合小剂量糖皮质激素治疗脓毒症的疗效及安全性评价[J].山西医药杂志，2017，46（8）：866-868.
[19] 薛骅，鲁丽利，向辉，等.乌司他丁联合氢化可的松治疗脓毒性休克的疗效及对血清因子的影响[J].中国临床药理学与治疗学，2019，24（3）：313-317.
[20] 陶小华，肖正武，邵忠华.老年脓毒血症患者血清炎症因子、NT-proBNP、PCT和外周血T淋巴细胞亚群变化[J].中国乡村医药，2018，25（12）：29-30.
[21] 王翔，李建国，李志峰，等.参附注射液联合糖皮质激素对脓毒血症患者PCT、NT-proBNP及炎症因子的影响[J].中国中医急症，2019，28（6）：954-957.
[22] 蒋佳维，许华，刘睿，等.间充质干细胞治疗脓毒症的研究进展[J].医学综述，2018，24（23）：4630-4634.
[23] 王伟，常平，李夏西，等.乌司他丁对严重脓毒症患者远期预后及体内降钙素原的影响[J].安徽医科大学学报，2016，51（5）：744-747.
[24] 陈瑞娟，关小容.乌司他丁辅助治疗重症脓毒血症的疗效及对细胞因子的影响[J].实用临床医药杂志，2015， 19（11）：130-132.
[25] 张宇，丁国娟，陈亚涛，等.乌司他丁对脓毒血症患者免疫功能的影响[J].实用药物与临床，2014，17（6）：728.
[26] 王珊珊.乌司他丁在脓毒血症、感染性休克治疗中的应用[J].中国基层医药，2013，20（11）：1721-1722.